Clinical Trial Research | Cardiovascular Medicine

Explore our active clinical trials below, highlighting the innovative research opportunities aimed at advancing cardiovascular care and improving patient outcomes.

Monica Ahluwalia, MD

Sponsor: Bristol Myers
A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten in Adults with Symptomatic Non-obstructive Hypertrophic Cardiomyopathy

Nir Ayalon, MD

Sponsor: Vectorious Medical Technologies
V-LAP system for wirelessly measuring and monitoring left atrial pressure (LAP) in patients with advanced Chronic Heart Failure

Wilson Colucci, MD

Sponsor: Lexicon Pharmaceuticals, Inc.
Effects of sotagliflozin on myocardial remodeling, function and gene expression in mice with hypertrophic cardiomyopathy

Deepa Gopal, MD

Sponsor: Alleviant Medical Inc
ALLAY-HF: Safety and Efficacy of the Alleviant System for No-Implant Interatrial Shunt Creation in Patients with Chronic Heart Failure

Robert Helm, MD

Sponsor: Cardathea Inc.
Body Surface Mapping of Conduction System

Sponsor: NIH (Pass-through: Northwestern University)
REACT-AF: The Rhythm Evaluation for Anticoagulation with Continuous Monitoring of Atrial Fibrillation Trial (UH3)

Darae Ko, MD

Sponsor: NIH (Pass-through: Mount Sinai Medical Center)
CTSN/PACeS trial (U01)

Ashvin Pande, MD

Sponsor: NIH (Pass-through: New York University)
PETRACT-1/2 Pulmonary Embolism: Thrombus Removal with Catheter-Directed Therapy: The PE-TRACT Trial (UH3)

David Pimentel, MD

Sponsor: Eli Lilly and Company
J3E-MC-EZDB: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of LY3540378 in Adults with Worsening Chronic Heart Failure with Preserved Ejection Fraction

Frederick Ruberg, MD

Sponsor: Anumana, Inc.
ECG-AI Software Study for Detecting Cardiac Amyloidosis

Sponsor: Eidos Therapeutics, Inc.
Act Early

Sponsor: TriNetX / AstraZeneca Pharmaceuticals
TeATTRo Registry – ATTR Project (Database Pilot)

Omar Siddiqi, MD

Sponsor: BMS (Pass-through: Mass General Brigham)
AbatacepT foR ImmUne checkpoint inhibitor associated Myocard

Sponsor: Intellia Therapeutics, Inc.
MAGNITUDE: A Phase 3, Multinational, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NTLA-2001 in Participants with Transthyretin Amyloidosis with Cardiomyopathy (ATTR-CM)